Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 2/20 | 0.48 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.47 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583515 | 0.85 | NPC1 (0.56) | NPC1MAPK1TSHRLMNACSF1R | |
| SCHEMBL14514690 | 0.80 | NPC1 (0.53) | NPC1TSHRMEN1KMT2APRSS12 | |
| Hydrochloric Acid SCHEMBL5650486 | 0.79 | NPC1 (0.52) | NPC1TSHRMEN1KMT2APRSS12 | |
| SCHEMBL5650967 | 0.79 | PRSS12 (0.50) | MEN1HTTKMT2AHPSEPRSS12 | |
| SCHEMBL30685378 | 0.78 | NPC1 (0.54) | NPC1MAPK1TSHRLMNAALDH1A1 | |
| SCHEMBL22264782 | 0.78 | NPC1 (0.54) | NPC1MAPK1TSHRLMNAALDH1A1 | |
| SCHEMBL5649792 | 0.78 | PRSS12 (0.49) | PRSS12 | |
| SCHEMBL5648605 | 0.77 | RHEB (0.45) | MEN1HTTKMT2AHPSEPRSS12 | |
| SCHEMBL5667580 | 0.77 | PRSS12 (0.49) | NPC1LMNAHPSEPRSS12MAPT | |
| SCHEMBL5649708 | 0.76 | PRSS12 (0.47) | MAPK1TSHRMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | NPC1 1699/4885MAPK1 948/4885TSHR 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.